UCB Acquires IMIDomics' Patient Insight Business to Advance Precision Medicine in Immune-Mediated Inflammatory Diseases
Key Insights
UCB (search) has acquired IMIDomics (search)' Patient Insight Business, gaining access to one of the world's most comprehensive multi-omic datasets for immune-mediated inflammatory diseases (search) built over 18 years.
The acquisition provides UCB (search) with proprietary genetics and omics datasets, advanced analytics platforms, and access to samples from over 17,000 patients through the IMID Biobank at Vall d'Hebron Institute of Research (search).
The strategic move enhances UCB (search)'s ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient stratification approaches using machine learning and AI technologies.
UCB (search) announced on May 1, 2026, the acquisition of IMIDomics (search)' Patient Insight Business, a strategic move that provides the Belgian biopharmaceutical company with direct access to one of the most advanced, deeply curated human datasets in immunology. The acquisition significantly enhances UCB's ability to accelerate precision-driven therapeutic discovery and development in immune-mediated inflammatory diseases (search) (IMIDs (search)).
Comprehensive Data Platform for Drug Discovery
The acquired Patient Insight Business represents more than 18 years of clinical and molecular data generation, integrating epidemiological information, detailed clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples. This extensive dataset is collected through a robust clinical network of more than 300 investigators and 130+ recruiting centers.
"The acquisition of IMIDomics (search)' Patient Insight Business represents a significant step in our strategy to build the most robust, human data–driven platform in immune mediated diseases," said Alistair Henry, Executive Vice President & Chief Scientific Officer at UCB (search). "IMIDomics has spent a decade assembling a dataset and network that are simply not replicable in today's environment."
Access to World-Class Biobank Resources
The Patient Insights Business is powered by samples stored in the IMID Biobank at the Vall d'Hebron Institute of Research (search) (VHIR (search)) in Barcelona, one of the most comprehensive IMID-focused biobanks globally. The biobank contains contributions from over 17,000 patients, providing an unprecedented resource for understanding disease mechanisms and developing targeted therapies.
Under the acquisition terms, UCB (search) will gain access to IMIDomics (search)' skilled personnel and laboratories, proprietary genetics and omics datasets, analytic platform, and established partnerships. This includes the contractual framework enabling continued access to VHIR (search)-controlled human biological samples and associated data.
Advanced Analytics and AI Integration
The precision medicine platform applies advanced biostatistics, machine learning, and artificial intelligence to uncover new therapeutic targets, responder biomarkers, and disease subtype insights. These capabilities are designed to meaningfully de-risk and accelerate drug development by providing molecularly informed patient stratification approaches.
Professor Sara Marsal, Founder and Chief Medical Officer of IMIDomics (search) Inc, emphasized the strategic alignment: "Our mission has always been to bring the patient, through their biology, clinical journeys, and data, into every stage of drug development. UCB (search) is the ideal partner to scale that mission. With their scientific depth and commitment to innovation, we are confident the Patient Insight Engine will continue to unlock meaningful breakthroughs for people living with IMIDs (search)."
Strategic Impact on UCB's Portfolio
UCB (search), a global biopharmaceutical company with more than 9,000 employees in approximately 40 countries, generated revenue of €7.7 billion in 2025. The company focuses on discovering and developing innovative medicines for severe diseases of the immune system and central nervous system.
The integration of IMIDomics (search)' capabilities and team is expected to elevate UCB (search)'s ability to discover and develop medicines that are truly informed by patient biology. Financial details of the acquisition agreement were not disclosed.
IMIDomics (search) is dedicated to discovering and developing first-in-class medicines for immune-mediated inflammatory diseases (search), particularly for patients without treatment options or unresponsive to current treatments. The company's proprietary Clinical Discovery Engine™ integrates comprehensive longitudinal clinical, epidemiological, and biomolecular data from IMID patients, enabling the identification of disease mechanisms and development of precision medications.